AI Engines For more Details: Perplexity Kagi Labs You
Dental Health: Xylitol has been shown to have several beneficial effects on dental health:
Blood Sugar Management: Xylitol has a low glycemic index and does not cause a rapid increase in blood glucose levels after consumption. It can be a suitable sugar substitute for individuals with diabetes or those aiming to manage blood sugar levels. However, excessive consumption of xylitol may still contribute to caloric intake and should be consumed in moderation.
Weight Management: Xylitol is lower in calories compared to sucrose (table sugar) and other sugar alcohols, making it a popular alternative for individuals seeking to reduce calorie intake or manage their weight. It provides sweetness without the same caloric impact as regular sugar.
Digestive Health: Xylitol is known for its laxative effect when consumed in large amounts. While small to moderate doses of xylitol are well-tolerated by most individuals, excessive intake may cause gastrointestinal discomfort, bloating, gas, and diarrhea, particularly in sensitive individuals or those with irritable bowel syndrome (IBS).
Ear Health: Some research suggests that xylitol may have benefits for ear health, particularly in preventing acute otitis media (middle ear infection) in children. Chewing gum or consuming lozenges containing xylitol may help reduce the risk of ear infections by inhibiting the growth of bacteria in the upper respiratory tract.
Bone Health: Limited studies suggest that xylitol may have potential benefits for bone health by promoting calcium absorption and bone density. However, more research is needed to fully understand the effects of xylitol on bone metabolism and its potential role in preventing osteoporosis or improving bone health.
Rank | Probiotic | Impact |
---|---|---|
species | Lactobacillus acidophilus | Increases |
species | Lactobacillus crispatus | Increases |
species | Lactobacillus gasseri | Increases |
species | Lactobacillus helveticus | Increases |
species | Lactobacillus jensenii | Increases |
species | Lactobacillus johnsonii | Increases |
species | Lactobacillus kefiranofaciens | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
Acne | 1.3 | 0.8 | 0.63 |
ADHD | 2.2 | 2.2 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.4 | 0.5 |
Allergic Rhinitis (Hay Fever) | 2.2 | 0.9 | 1.44 |
Allergies | 1.7 | 2.6 | -0.53 |
Allergy to milk products | 0.5 | 2.3 | -3.6 |
Alopecia (Hair Loss) | 1.8 | -1.8 | |
Alzheimer's disease | 4.9 | 2.5 | 0.96 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | 4.2 | -2 |
Ankylosing spondylitis | 3.2 | 3.7 | -0.16 |
Anorexia Nervosa | 3.2 | 1.2 | 1.67 |
Antiphospholipid syndrome (APS) | 0.2 | -0.2 | |
Asthma | 1.3 | 1.6 | -0.23 |
Atherosclerosis | 1.5 | 0.6 | 1.5 |
Atrial fibrillation | 1.7 | 3.3 | -0.94 |
Autism | 6.1 | 5.7 | 0.07 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 1.4 | 2.4 | -0.71 |
Brain Trauma | 1.7 | 0.8 | 1.13 |
Breast Cancer | 0.2 | -0.2 | |
Carcinoma | 2.3 | 2 | 0.15 |
Celiac Disease | 3.4 | 3 | 0.13 |
Cerebral Palsy | 2.1 | 0.5 | 3.2 |
Chronic Fatigue Syndrome | 3.7 | 3.3 | 0.12 |
Chronic Kidney Disease | 2.5 | 1.7 | 0.47 |
Chronic Lyme | 0.8 | 0.8 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 0.8 | 0.63 |
Chronic Urticaria (Hives) | 1.2 | 0.5 | 1.4 |
Coagulation / Micro clot triggering bacteria | 1.8 | 1.8 | |
Colorectal Cancer | 1 | 3.1 | -2.1 |
Constipation | 0.4 | 2.6 | -5.5 |
Coronary artery disease | 2.1 | 1 | 1.1 |
COVID-19 | 7 | 6.3 | 0.11 |
Crohn's Disease | 5.6 | 5.4 | 0.04 |
cystic fibrosis | 0.8 | 0.8 | |
deep vein thrombosis | 1.4 | 1.4 | |
Depression | 5.4 | 7.3 | -0.35 |
Dermatomyositis | 1.2 | -1.2 | |
Eczema | 0.2 | 1.4 | -6 |
Endometriosis | 1.5 | 1.4 | 0.07 |
Eosinophilic Esophagitis | 0.3 | 0.8 | -1.67 |
Epilepsy | 3.6 | 3.4 | 0.06 |
erectile dysfunction | 0.8 | -0.8 | |
Fibromyalgia | 2.5 | 1.4 | 0.79 |
Functional constipation / chronic idiopathic constipation | 3.2 | 4.3 | -0.34 |
gallstone disease (gsd) | 0.8 | 1 | -0.25 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 1.5 | -0.67 |
Generalized anxiety disorder | 1.1 | 0.8 | 0.38 |
giant cell arteritis | 0.3 | -0.3 | |
Glioblastoma | 1.2 | 0.5 | 1.4 |
Gout | 0.8 | 2.5 | -2.13 |
Graves' disease | 2.6 | 2.5 | 0.04 |
Halitosis | 0.9 | 0.9 | 0 |
Hashimoto's thyroiditis | 0.8 | 2.7 | -2.38 |
Hidradenitis Suppurativa | 0.7 | 0.2 | 2.5 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.8 | 1.6 | -1 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.1 | 4 |
hyperglycemia | 1.4 | 0.6 | 1.33 |
Hyperlipidemia (High Blood Fats) | 2.6 | 2.6 | |
hypersomnia | 1.1 | 1.1 | |
hypertension (High Blood Pressure | 5 | 2.8 | 0.79 |
Hypothyroidism | 2.2 | 2.2 | |
Hypoxia | 1.7 | -1.7 | |
IgA nephropathy (IgAN) | 1.9 | 1.1 | 0.73 |
Inflammatory Bowel Disease | 5 | 1.6 | 2.13 |
Insomnia | 1.7 | 2.3 | -0.35 |
Intelligence | 0.6 | 1.9 | -2.17 |
Intracranial aneurysms | 0.6 | 0.9 | -0.5 |
Irritable Bowel Syndrome | 3.6 | 3.9 | -0.08 |
Juvenile idiopathic arthritis | 0.6 | -0.6 | |
Liver Cirrhosis | 2.9 | 4.1 | -0.41 |
Long COVID | 7.5 | 6.6 | 0.14 |
Low bone mineral density | 1.2 | 1 | 0.2 |
Lung Cancer | 1.4 | 0.2 | 6 |
ME/CFS with IBS | 0.6 | 0.2 | 2 |
ME/CFS without IBS | 0.8 | 0.8 | |
Menopause | 0.2 | -0.2 | |
Metabolic Syndrome | 5.9 | 5.9 | 0 |
Mood Disorders | 6.7 | 8.7 | -0.3 |
multiple chemical sensitivity [MCS] | 0.2 | 0.6 | -2 |
Multiple Sclerosis | 5 | 2 | 1.5 |
Multiple system atrophy (MSA) | 0.2 | 0.6 | -2 |
myasthenia gravis | 0.6 | 0.2 | 2 |
Neuropathy (all types) | 0.8 | 2.3 | -1.87 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 1.4 | -1.33 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.2 | 1.8 | 0.78 |
Obesity | 4.8 | 3.6 | 0.33 |
obsessive-compulsive disorder | 3.4 | 3.2 | 0.06 |
Osteoarthritis | 1.2 | -1.2 | |
Osteoporosis | 2.5 | 2.5 | 0 |
Parkinson's Disease | 5.5 | 2.7 | 1.04 |
Polycystic ovary syndrome | 0.9 | 2.2 | -1.44 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | 0 |
Premenstrual dysphoric disorder | 1 | 0.4 | 1.5 |
primary biliary cholangitis | 0.2 | 0.8 | -3 |
Psoriasis | 2.5 | 1.5 | 0.67 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.6 | 4.6 | 0 |
Rosacea | 0.8 | 0.8 | 0 |
Schizophrenia | 2.5 | 4.7 | -0.88 |
scoliosis | 1.3 | -1.3 | |
sensorineural hearing loss | 0.6 | 0.6 | |
Sjögren syndrome | 3.1 | 1.6 | 0.94 |
Sleep Apnea | 1.8 | 0.6 | 2 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
Stress / posttraumatic stress disorder | 1.8 | 2.9 | -0.61 |
Systemic Lupus Erythematosus | 3.6 | 4.2 | -0.17 |
Tic Disorder | 0.7 | 0.8 | -0.14 |
Tourette syndrome | 1.2 | 1.2 | |
Type 1 Diabetes | 2.4 | 3.8 | -0.58 |
Type 2 Diabetes | 5.1 | 5.3 | -0.04 |
Ulcerative colitis | 4.7 | 4.1 | 0.15 |
Unhealthy Ageing | 1.4 | 2.1 | -0.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.